United Therapeutics Director Sells Small Stake, Exercises Options as Analysts Raise Targets
United Therapeutics director Christopher Causey sold 20 shares of UTHR on March 4, 2026, for $9,803 and simultaneously exercised options to buy 20 shares at $119.76. The transactions were executed under a pre-arranged Rule 10b5-1 plan. The stock is trading near its InvestingPro Fair Value after a 58% year-over-year gain. Several analysts have raise…